Ebola Virus Disease Therapeutics: Breakthroughs in Clinical Treatment

By Editorial Team -
Ebola Virus Disease (EVD) is a severe, often fatal illness in humans. Historically managed purely through supportive care, the landscape of Ebola virus disease therapeutics has shifted dramatically. Thanks to landmark clinical trials, clinicians now deploy highly targeted, FDA-approved therapies that significantly reduce mortality rates.

The Evolution of Ebola Therapeutics: The PALM Trial Benchmark

The turning point for modern Ebola virus disease therapeutics occurred during the 2018–2020 outbreak in the Democratic Republic of the Congo. The Pamoja Tulinde Maisha (PALM) randomized controlled trial, published in The New England Journal of Medicine and indexed on PubMed, revolutionized treatment protocols.


The PALM trial evaluated four distinct therapeutic candidates. It conclusively demonstrated that targeted monoclonal antibodies offered a vastly superior survival advantage compared to standard care and early antiviral small molecules.

FDA-Approved Monoclonal Antibodies for Ebola

Monoclonal antibodies are currently the gold standard in Ebola treatment. They function by specifically targeting and neutralizing the viral glycoprotein, preventing the virus from entering host cells. Two therapies have received full FDA approval:

1. Inmazeb (REGN-EB3)

  • What it is: A cocktail combination of three human monoclonal antibodies (atoltivimab, maftivimab, and odesivimab).
  • Mechanism: It binds to three non-overlapping, distinct epitopes on the Ebola virus glycoprotein. This multi-target approach reduces the risk of the virus escaping treatment via single mutations.
  • Clinical Evidence: Demonstrated a significant reduction in mortality during the PALM trial, especially when administered early in the infection cycle.

2. Ebanga (Ansuvimab-zykl / mAb114)

  • What it is: A single human monoclonal antibody.
  • Mechanism: Originally isolated from a survivor of the 1995 Ebola outbreak in Kikwit, Ebanga binds to the glycan cap and core domain of the viral glycoprotein. This block prevents host cell receptor interaction.
  • Clinical Advantage: Offers an efficient, single-antibody delivery mechanism with proven high efficacy in reducing viral loads.

Evaluated Antiviral Drugs and Legacy Therapies

While monoclonal antibodies lead the field, several other Ebola antiviral drugs and small molecules have undergone rigorous clinical testing.

Therapeutic Name Drug Type Clinical Status & Efficacy Notes
Remdesivir (GS-5734) RNA Polymerase Inhibitor Evaluated in the PALM trial; showed higher mortality rates compared to Inmazeb and Ebanga.
ZMapp Chimeric Antibody Cocktail An early benchmark therapy. It has been largely superseded by newer FDA-approved formulations.
Favipiravir (T-705) Oral Antiviral Tested in West African outbreaks; clinical data remains mixed and inconclusive.

The Critical Role of Optimized Supportive Care

While specific Ebola virus disease therapeutics are essential, they do not replace advanced supportive care. Clinical protocols emphasize that the combination of targeted drugs and aggressive supportive therapies yields the highest survival rates. Key supportive actions include:

  • Intravenous fluid resuscitation to combat severe dehydration.
  • Electrolyte stabilization to prevent cardiac complications.
  • Hemodynamic monitoring and respiratory support.
  • Empiric treatment of concurrent secondary bacterial infections.

Future Pipelines: Broad-Spectrum and Combination Therapies

The future of Ebola treatment focuses on overcoming two major challenges: viral mutations and species diversity (such as the Sudan ebolavirus).

Emerging pipelines are exploring broadly protective antibodies like MBP134AF, designed to target multiple Ebolavirus species simultaneously. Additionally, researchers are studying combination strategies that pair monoclonal antibodies with small-molecule antivirals to prevent drug resistance and extend the therapeutic window.

Conclusion

The shift from empirical supportive care to targeted Ebola virus disease therapeutics has rewritten the prognosis for patients infected with this deadly pathogen. With Inmazeb and Ebanga leading clinical protocols, early diagnosis and rapid drug administration remain the most critical factors in saving lives.

Comments

Post a Comment

Popular posts from this blog

Dr Peter McCullough: How to Detox Spike Protein from Body (2026 Update)

By Editorial Team -
Image
Base Spike Detox According to Dr Peter McCullough (in a X/Twitter post): Base Spike Detox is what I am currently using in my practice for those who have had COVID-19 multiple times, one or more of the COVID-19 vaccines, or both and believe persistent SARS-CoV-2 Spike protein could be causing problems in their body.  I have arrived, based on the emerging scientific literature (1) and my clinical observation, that three OTC products are essential as a triple base combination: Nattokinase 2000 FU (100 mg) twice a day  — take on an empty stomach Bromelain 500 mg once a day  — take on an empty stomach Nano/Liposomal Curcumin 500 mg twice a day  — take with food How long should I take this? Dr. McCullough recommends a minimum of 3 months , with many patients requiring 6–12 months or longer. Progress can be tracked via a spike protein antibody test (available through Labcorp in m...
Read more

Dr Peter McCullough: How to Measure Your Spike Protein Antibody (2026)

By Editorial Team -
Image
Dr. McCullough explained (1) that the spike protein is an engineered, synthetic molecule roughly 1,200 amino acids long and resistant to degradation by the body’s normal proteases. He described how the protein was modified in laboratory settings (notably at the Wuhan Institute of Virology) to tightly bind to the ACE2 receptor, which is found throughout the body—in the lungs, heart, endothelium, kidneys, and brain. Because this receptor regulates angiotensin metabolism, older individuals with fewer ACE2 sites catabolize the spike less efficiently, leading to worse outcomes. Whether introduced by infection or by genetic‑code‑based vaccines, McCullough asserted, the persistent spike damages tissues directly and through chronic inflammation, micro‑clotting, and autoimmune cross‑reactivity. He cited more than 300 papers documenting spike deposits in the heart, brain, and vascular tissue, relating these findings to post‑vaccine myocarditis, strokes, and clotting disorders. A chief diagnostic...
Read more

How to Remove Spike Protein from Body: FLCCC I-Recover Protocol

By Editorial Team -
Image
Can you remove spike proteins from your body? Dr. Paul Marik and Dr. Pierre Kory are pleased to introduce the I-RECOVER: Post-Vaccine Treatment protocol, designed to help people who have experienced adverse symptoms after a COVID vaccine. Kory and Marik are both part of the FLCCC*, which was founded in 2020 to share early treatment protocols for COVID-19. Kory is an ICU specialist, triple board certified in internal medicine, critical care and pulmonary medicine. He now runs a private tele-health practice specializing in the treatment of COVID-19, so-called "long-COVID" and post-vaccine syndrome. *The FLCCC Alliance is now the  Independent Medical Alliance Note that there are significant overlaps between the symptoms and features of long COVID/long-hauler syndrome and post-vaccine syndrome. However, a number of clinical features appear to be characteristic of post-vaccine syndrome; most notably, severe neurological symptoms appear to be more common following vaccination. To c...
Read more

McCairn–Edogawa Protocol: Viral Long COVID Cure from Japan?

By Editorial Team -
Image
The McCairn Protocol (Edogawa–McCairn Protocol): Overview and Mechanistic Rationale The McCairn Protocol (also referred to as the Edogawa–McCairn Protocol ) is an experimental, two-phase treatment approach promoted by Kevin McCairn in collaboration with Edogawa Hospital. It is primarily proposed for individuals with Long COVID and post-mRNA vaccine–associated syndromes , targeting hypothesized drivers such as persistent spike protein, amyloid-like fibrin microclots, autoantibodies, chronic inflammation, and associated vascular or neurological dysfunction. Phase 1: Double Filtration Plasmapheresis (DFPP) / Plasma Adsorption (“Cleansing”) Double Filtration Plasmapheresis (DFPP) is a specialized form of therapeutic apheresis currently used in parts of Asia, including Japan, for selected autoimmune, neurological, and metabolic conditions. Procedure Blood is withdrawn, often via a large-bore catheter (e.g., internal jugular access). It is passed through a dual-filtration syste...
Read more

Find a Doctor to prescribe Hydroxychloroquine, Ivermectin and Early Outpatient Treatments (2025)

By Editorial Team -
Image
Treatment should start based on clinical suspicion as soon as possible, preferably within the first 3 days of symptoms. Perform PCR testing, but do not withhold treatment pending results. 'Early' treatment will make significant difference in outcome as opposed to late treatment.  Related: How can I get Ivermectin? See the directory of professionals in US below. Directory of Doctors (by State) Prescribing Effective Outpatient COVID-19 Therapy USA ​ MULTIPLE STATES (Telemedicine or online consultation) The Wellness Company ( twc.health ) Medical Specialty: Family Medicine, Functional Medicine Supported Protocols: I-PREVENT (COVID Protection), I-CARE (Early at-home treatment), I-RECOVER (Long COVID and Post-Vaccine treatment) Dr. Miguel Antonatos (IVM) (855) 767-8559  https://text2md.com (States: AL, AZ, CO, FL, GA, IA, ID, IL, KS, KY, MD, ME, MI, MN, MS, ND, NE, NJ, NV, OK, SC, SD, TN, UT, VT, WA, WI, WV) ...
Read more

Dr Peter McCullough: Povidone Iodine, Oral and Nasal Hygiene (2026)

By Editorial Team -
Image
Dr. Peter McCullough is an internist, cardiologist, epidemiologist, a full professor of medicine at Texas A&M College of Medicine in Dallas, USA. He also has a master's degree in public health and is known for being one of the top five most-published medical researchers in the United States and is the editor of two medical journals. McCullough Protocol 2022 Update: Azelastine Nasal Spray for Prevention of SARS-CoV-2 Infections: A Phase 2 Randomized Clinical Trial ( JAMA 2025 ) Everyone is familiar with nasal and oral swab testing for COVID-19. It should be obvious the virus is replicating in the nose, and with Omicron, the speed of replication has become much greater than the prior strains of the virus. Thus, there is a wonderful opportunity to reduce viral replication, in fa...
Read more

Ebola Outbreak in Congo 2026: 87 Dead, No Vaccine for New Strain as Virus Crosses into Uganda

By Editorial Team -
Image
A fast-spreading Ebola outbreak in the DRC's Ituri province has killed at least 87 people across 246 suspected cases — and experts warn the Bundibugyo strain driving it has no approved vaccine. By One Day MD Editorial Team · Updated May 17, 2026 · 6 min read 87+ Deaths confirmed 246 Suspected cases 13 Lab-confirmed cases 0 Approved vaccines A deadly Ebola outbreak has been confirmed in the Democratic Republic of Congo (DRC), health authorities announced on May 15, 2026 — and it is already spreading beyond the country's borders. At least 87 people have died and 246 suspected cases have been recorded in Ituri province, eastern DRC, making this the country's 17th Ebola outbreak since the virus was first identified there in 1976. What makes this outbreak uniquely alarming is the strain involved. Unlike the majority of Congo's previous outbreaks — which were caused by the well...
Read more

FLCCC I-Recover Protocol: Post Vaccine Treatment Protocol (2025)

By Editorial Team -
Image
Over the last three years, the COVID-19 pandemic has transformed almost every aspect of our lives before we've had time to stop and question it. Although no official definition exists for post-COVID-vaccine syndrome, a temporal correlation between a patient receiving a COVID-19 vaccine and beginning or worsening of clinical manifestations is sufficient to diagnose as a COVID-19 vaccine-induced injury, when the symptoms are unexplained by other concurrent causes. Dr. Paul Marik and Dr. Pierre Kory are pleased to introduce the I-RECOVER: Post-Vaccine Treatment protocol, designed to help people who have experienced adverse symptoms after a COVID vaccine. Kory and Marik are both part of the FLCCC ( The FLCCC Alliance is now the Independent Medical Alliance ), which was founded in 2020 to share early treatment protocols for COVID-19. Kory is an ICU specialist, triple board certified in internal medicine, critical care and pulmonary medicine. He now runs a priva...
Read more

Dr. Peter McCullough's Spike Protein Detox Protocol: Base Spike Detox Explained

By Editorial Team -
Image
A clinician-developed regimen of nattokinase, bromelain, and curcumin for clearing persistent SARS-CoV-2 spike protein — with dosing, safety guidance, monitoring, and full FAQ.   Editorial Team   |  Originally published March 2023  |  Last updated December 30, 2025  |  Reviewed against published literature and Dr. McCullough's 2025 clinical updates ⚠️ Medical Disclaimer — Please Read First This article is for  educational purposes only  and does not constitute medical advice, diagnosis, or treatment. The Base Spike Detox protocol involves supplements with significant anticoagulant activity. Always consult a licensed physician before starting , especially if you are taking blood thinners, are pregnant or breastfeeding, have a bleeding disorder, or are treating a child. For a virtual consultation with a physician familiar with this protocol,...
Read more

Hantavirus Outbreak 2026: Symptoms, Deaths, Human Transmission and What You Need to Know

By Editorial Team -
Image
On 2 May 2026, a cluster of passengers with severe respiratory illness aboard a cruise ship was reported to the World Health Organization (WHO). The vessel was carrying 147 passengers and crew members. As of 4 May 2026, seven cases — including two laboratory-confirmed hantavirus infections and five suspected cases — had been identified. Among these cases were three deaths, one critically ill patient, and three individuals with mild symptoms. Illness onset occurred between 6 and 28 April 2026 and was characterized by fever, gastrointestinal symptoms, rapid progression to pneumonia, acute respiratory distress syndrome (ARDS), and shock. Further investigations remain ongoing. The outbreak response includes coordinated international public health measures such as in-depth epidemiological investigations, case isolation and medical care, patient evacuation, and laboratory testing. Human hantavirus infection is primarily acquired through contact with the urine, feces, or saliva of infected ro...
Read more

Labels

Show more

Archive

Show more